Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does VEDOLIZUMAB Cause C-reactive protein abnormal? 187 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 187 reports of C-reactive protein abnormal have been filed in association with VEDOLIZUMAB (ENTYVIO). This represents 0.3% of all adverse event reports for VEDOLIZUMAB.

187
Reports of C-reactive protein abnormal with VEDOLIZUMAB
0.3%
of all VEDOLIZUMAB reports
161
Deaths
176
Hospitalizations

How Dangerous Is C-reactive protein abnormal From VEDOLIZUMAB?

Of the 187 reports, 161 (86.1%) resulted in death, 176 (94.1%) required hospitalization, and 170 (90.9%) were considered life-threatening.

Is C-reactive protein abnormal Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for VEDOLIZUMAB. However, 187 reports have been filed with the FAERS database.

What Other Side Effects Does VEDOLIZUMAB Cause?

Off label use (21,017) Colitis ulcerative (13,455) Crohn's disease (9,759) Drug ineffective (8,424) Diarrhoea (7,493) Abdominal pain (6,401) Fatigue (5,477) Haematochezia (5,215) Frequent bowel movements (4,527) Arthralgia (4,028)

What Other Drugs Cause C-reactive protein abnormal?

METHOTREXATE (3,734) ADALIMUMAB (3,629) ETANERCEPT (3,592) ABATACEPT (3,402) LEFLUNOMIDE (3,279) TOCILIZUMAB (3,259) HYDROXYCHLOROQUINE (3,245) SULFASALAZINE (2,823) INFLIXIMAB (2,676) RITUXIMAB (2,608)

Which VEDOLIZUMAB Alternatives Have Lower C-reactive protein abnormal Risk?

VEDOLIZUMAB vs VELAGLUCERASE ALFA VEDOLIZUMAB vs VELCADE VEDOLIZUMAB vs VELETRI VEDOLIZUMAB vs VELIPARIB VEDOLIZUMAB vs VEMURAFENIB

Related Pages

VEDOLIZUMAB Full Profile All C-reactive protein abnormal Reports All Drugs Causing C-reactive protein abnormal VEDOLIZUMAB Demographics